Stocks
Neumora Therapeutics, Inc.NMRA
NASDAQHealthcareBiotechnology$0.38
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing novel therapies for neurological and psychiatric disorders, with a focus on depression and other CNS conditions. Its lead program, navacaprant, targets the kappa opioid receptor and is in late-stage trials, making it a closely watched name for investors seeking exposure to CNS drug development.
52W Range: $0.32-$3.65
Congressional Interest in Neumora Therapeutics, Inc. (NMRA)
No congressional trades have been disclosed for Neumora Therapeutics, Inc. (NMRA) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading NMRA?
No congressional trades found for this stock.